Emerging analytical separation techniques with high throughput potential for pharmaceutical analysis, part II: Novel chromatographic modes

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 6, 2010, Pages 530-547

  Dejaegher, Bieke ^a   Pieters, Sigrid ^a   Heyden, Yvan Vander ^a  

^a PHARMACEUTICAL INSTITUTE   (Belgium)

Author keywords

Hydrophilic Interaction Liquid Chromatography (HILIC); Polar Organic Solvent Chromatography (POSC); Supercritical Fluid Chromatography (SFC)

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ATENOLOL; CAFFEINE; CETIRIZINE; CLOZAPINE; CORTISONE; DACARBAZINE; DONEPEZIL; ESTRADIOL; FENOPROFEN; GABOXADOL; ISONIAZID; KETOPROFEN; LORATADINE; METHYLTESTOSTERONE; MURAGLITAZAR; NAPROXEN; OMEPRAZOLE; ONDANSETRON; OSELTAMIVIR; PRIMIDONE; PROGESTERONE; PROPOFOL; RITODRINE; TESTOSTERONE; THEOPHYLLINE; THYMINE; TOLBUTAMIDE; UNINDEXED DRUG; URACIL;

ANALYTIC METHOD; ENANTIOMER; HIGH THROUGHPUT SCREENING; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; SUPERCRITICAL FLUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL;

EID: 77955743775     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710791516030     Document Type: Review

References (53)

1. Alpert, A. J. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J. Chromatogr., 1990, 499, 177-196.
2. A Practical Guide to HILIC, A tutorial and application book, SeQuant AB: Sweden, Umeå, 2006.
3. Hemström, P.; Irgum, K. Hydrophilic interaction chromatography. J. Sep. Sci., 2006, 29, 1784-1821.
4. Jandera, P. Stationary phases for hydrophilic interaction chromatography, their characterization and implementation into multidimensional chromatography concepts. J. Sep. Sci., 2008, 31, 1421-1437.
5. Strege M. A. Hydrophilic interaction chromatography-electrospray mass spectrometry analysis of polar compounds for natural product drug discovery. Anal. Chem., 1998, 70, 2439-2445.
6. Li, W.; Li, Y.; Francisco, D. T.; Naidong, W. Hydrophilic interaction liquid chromatographic tandem mass spectrometric determination of atenolol in human plasma. Biomed. Chromatographia, 2005, 19, 385-393.
7. ®) in human plasma-with emphasis on method ruggedness. J. Chromatogr. B, 2005, 814, 105-114.
8. Song, Q.; Naidong, W. Analysis of omeprazole and 5-OH omeprazole in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry (HILIC-MS/MS) - Eliminating evaporation and reconstitution steps in 96-well liquid/liquid extraction. J. Chromatogr. B, 2006, 830, 135-142.
9. Xue, Y.-J.; Liu, J.; Unger, S. A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of muraglitazar in human plasma. J. Pharm. Biomed. Anal., 2006, 41, 979-988.
10. Cohen, S.; Lhuillier, F.; Mouloua, Y.; Vignal, B.; Favetta, P.; Guitton, J. Quantitative measurement of propofol and in main glucuroconjugate metabolites in human plasma using solid phase extraction-liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, 2007, 854, 165-172.
11. Ohmori, T.; Nakamura, M.; Tada, S.; Sugiyama, T.; Itoh, Y.; Udagawa, Y.; Hirano, K. A highly sensitive assay for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry. J. Chromatogr. B, 2008, 861, 95-100.
12. Apostolou, C.; Kousoulos, C.; Dotsikas, Y.; Loukas, Y. L. Comparison of hydrophilic interaction and reversed-phase liquid chromatography coupled with tandem mass spectrometric detection for the determination of three pharmaceuticals in human plasma. Biomed. Chromatogr., 2008, 22, 1393-1402.
13. Guitton, J.; Coste, S.; Guffon-Fouilhoux, N.; Cohen, S.; Manchon, M.; Guillaumont, M. Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B, 2009, 877, 149-154.
14. Huang, L.; Marzan, F.; Jayewardene, A. L.; Lizak, P. S.; Li, X.; Aweeka, F. T. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J. Chromatogr. B, 2009, 877, 285-290.
15. Liu; Y.; Zhang, W.; Yang, Y. Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole- carboxamide in human plasma. Talanta, 2008, 77, 412-421.
16. Lindegårdh, N.; Hanpithakpong, W.; Wattanagoon, Y.; Singhasivanon, P.; White, N. J.; Day, N. P. J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J. Chromatogr. B, 2007, 859, 74-83.
17. Kall, M. A.; Fu, I.; Dige, T.; Vallano, P.; Woolf, E.; Jørgensen, M. Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. J. Chromatogr. B, 2007, 858, 168-176.
18. Vree, T. B.; Lagerwerf, A. J.; Bleeker, C. P.; de Grood P. M. R. M. Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J. Chromatogr. B, 1999, 721, 217-228.
19. Louw, S.; Pereira, A. S.; Lynen, F.; Hanna-Brown, M.; Sandra, P. Serial coupling of reversed-phase and hydrophilic interaction liquid chromatography to broaden the elution window for the analysis of pharmaceutical compounds. J. Chromatogr. A, 2008, 1208, 90-94.
20. Kawano, S.-I. Analysis of impurities in streptomycin and dihydrostreptomycin by hydrophilic interaction chromatography/electrospray ionization quadrupole ion trap/time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom., 2009, 23, 907-914.
21. Wang, X.; Li, W.; Rasmussen, H. T. Orthogonal method development using hydrophilic interaction chromatography and reversed-phase high-performance liquid chromatography for the determination of pharmaceuticals and impurities. J. Chromatogr. A, 2005, 1083, 58-62.
22. Pack, B. W.; Risley, D. S. Evaluation of a monolithic silica column operated in the hydrophilic interaction chromatography mode with evaporative light scattering detection for the separation and detection of counter-ions. J. Chromatogr. A, 2005, 1073, 269-275.
23. ® CAD detector. J. Pharm. Biomed. Anal., 2009, 50, 809-814.
24. Ali, M. S.; Ghori, M.; Rafiuddin, S.; Khatri, A. R. A new hydrophilic interaction liquid chromatographic (HILIC) procedure for the simultaneous determination of pseudoephedrine hydrochloride (PSH), diphenhydramine hydrochloride (DPH) and dextromethorphan hydrobromide (DXH) in cough-cold formulations. J. Pharm. Biomed. Anal., 2007, 43, 158-167.
25. Risley, D. S.; Yang, W. Q.; Peterson, J. A. Analysis of mannitol in pharmaceutical formulations using hydrophilic interaction liquid chromatography with evaporative light-scattering detection. J. Sep. Sci., 2006, 29, 256-264.
26. Guidelines prepared within the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH), Specifications: test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances, Q6A, 2005, 1-25, http://www.ich.org
27. th ed., United States Pharmacopoeial Convention, Rockville, MD, USA, 2006.
28. th 2006, CPMP/SWP/5199/02, EMEA/CHMP/QWP/25134/2006.
29. Guidelines prepared within the International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH), Validation of Analytical Procedures: Text and Methodology, Q2 (R1), 2005, 1-13, http://www.ich.org
30. United States Food and Drug Administration (FDA), Department of Health and Human Services, Guidance for Industry: Bioanalytical Method Validation, http://www.fda.gov
31. ACTG guidelines for method development and validation based on (and including) FDA guidelines dated by 2001, Version 2, 2005.
32. Mangelings, D.; Vander Heyden, Y. Chiral separations in sub-and supercritical fluid chromatography. J. Sep. Sci., 2008, 31, 1252-1273.
33. Taylor, L. T. Supercritical fluid chromatography for the 21st century. J. Supercrit. Fluids, 2009, 47, 566-573.
34. Ates, H.; Mangelings, D.; Vander Heyden, Y. High throughput screening and method-development strategies to separate chiral drug compounds in HPLC, SFC and CE, In: Ahuja, S. Ed.; Chiral separation methods for pharmaceutical and biotechnology products. John Wiley and Sons, New Jersey, 2010, In press.
35. Brunelli, C.; Zhao, Y.; Brown, M.-H.; Sandra, P. Development of a supercritical fluid chromatography high-resolution separation method suitable for pharmaceuticals using cyanopropyl silica. J. Chromatogr. A, 2008, 1185, 263-272.
36. Berger, T. A.; Wilson, W. H. High-speed screening of combinatorial libraries by gradient packed-column supercritical fluid chromatography. J. Biochem. Biophys. Methods, 2000, 43, 77-85.
37. Maftouh, M.; Granier-Loyaux, C.; Chavana, E.; Marini, J.; Pradines, A.; Vander Heyden, Y.; Picard, C. Screening approach for chiral separation of pharmaceuticals Part III. Supercritical fluid chromatography for analysis and purification in drug discovery. J. Chromatogr. A, 2005, 1088, 67-81.
38. White, C. Integration of supercritical fluid chromatography into drug discovery as a routine support tool Part I. Fast chiral screening and purification. J. Chromatogr. A, 2005, 1074, 163-173.
39. White, C.; Burnett, J. Integration of supercritical fluid chromatography into drug discovery as a routine support tool II. Investigation and evaluation of supercritical fluid chromatography for achiral batch purification. J. Chromatogr. A, 2005, 1074, 175-185.
40. Zeng, L.; Xu, R.; Laskar, D. B.; Kassel, D. B. Parallel supercritical fluid chromatography/mass spectrometry system for high throughput enantioselective optimization and separation. J. Chromatogr. A, 2007, 1169, 193-204.
41. de la Puente, M. L.; White, C. T.; Rivera-Sagredo, A.; Reilly, J.; Burton, K.; Harvey, G. Impact of normal-phase gradient elution in chiral chromatography: a novel, robust, efficient and rapid chiral screening procedure. J. Chromatogr. A, 2003, 983, 101-114.
42. Hsieh, Y.; Favreau, L.; Schwerdt, J.; Chen K. C. Supercritical fluid chromatography/tandem mass spectrometric method for analysis of pharmaceutical compounds in metabolic stability samples. J. Pharm. Biomed. Anal., 2006, 40, 799-804.
43. Coe, R. A.; Rathe, J. O.; Lee, J. W. Supercritical fluid chromatography-tandem mass spectrometry for fast bioanalysis of R/S-warfarin in human plasma. J. Pharm. Biomed. Anal., 2006, 42, 573-580.
44. Gyllenhaal, O. Packed column supercritical fluid chromatography of a peroxysome proliferator-activating receptor agonist drug Achiral and chiral purity of substance, formulation assay and its enantiomeric purity. J. Chromatogr. A, 2004, 1042, 173-180.
45. Lundgren, J.; Salomonsson, J.; Gyllenhaal, O.; Johansson, E. Supercritical fluid chromatography of metoprolol and analogues on aminopropyl and ethylpyridine silica without any additives. J. Chromatogr. A, 2007, 1154, 360-367.
46. Simms, P. J.; Jeffries, C. T.; Zhao, X.; Huang, Y.; Arrhenius, T. Gradient elution of organic acids on a p-cyclodextrin column in the polar organic mode and its application to drug discovery. J. Chromatogr. A, 2004, 1052, 69-75.
47. Matthijs, N.; Maftouh, M.; Vander Heyden, Y. Screening approach for chiral separation of pharmaceuticals IV. Polar organic solvent chromatography. J. Chromatogr. A, 2006, 1111, 48-61.
48. Matthijs, N., Maftouh, M.; Vander Heyden, Y. Chiral separation strategy in polar organic solvent chromatography and performance comparison with normal-phase liquid and supercritical-fluid chromatography. J. Sep. Sci., 2006, 29, 1353-1362.
49. Ates, H.; Mangelings, D.; Vander Heyden, Y. Chiral separations in polar organic solvent chromatography: Updating a screening strategy with new chlorine-containing polysaccharide-based selectors. J. Chromatogr. B, 2008, 875, 57-64.
50. Matthijs, N.; Perrin, C.; Maftouh, M.; Massart, D. L.; Vander Heyden, Y. Definition and system implementation of strategies for method development of chiral separations in normal-or reversedphase liquid chromatography using polysaccharide-based stationary phases. J. Chromatogr. A, 2004, 1041, 119-133.
51. Cass, Q. B.; Watanabe, C. S. F.; Rabi, J. A.; Bottari, P. Q.; Costa, M. R.; Nascimento, R. M.; Cruz, J. E. D.; Ronald, R. C. Polysaccharide-based chiral phase under polar organic mode of elution in the determination of the enantiomeric purity of emtricitabine an anti-HIV analogue nucleoside. J. Pharm. Biomed. Anal., 2003, 33, 581-587.
52. Cirilli, R.; Ferretti, R.; Gallinella, B.; De Santis, E.; Zanitti, L.; La Torre, F. High-performance liquid chromatography enantioseparation of proton pump inhibitors using the immobilized amylosebased Chiralpak IA chiral stationary phase in normal-phase, polar organic and reversed-phase conditions. J. Chromatogr. A, 2008, 1177, 105-113.
53. Ferretti, R.; Gallinella, B.; La Torre, F.; Zanitti, L.; Turchetto, L.; Mosca, A.; Cirilli, R. Direct high-performance liquid chromatography enantioseparation of terazosin on an immobilised polysaccharide-based chiral stationary phase under polar organic and reversed-phase conditions. J. Chromatogr. A, 2009, 1216, 5385-5390.